{"id":"takecab","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Potassium-transporting ATPase"},"_scrapedAt":"2026-03-28T04:47:10.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Duodenal ulcer disease","diseaseId":"duodenal-ulcer-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gastric ulcer","diseaseId":"gastric-ulcer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gastro-esophageal reflux disease with esophagitis","diseaseId":"gastro-esophageal-reflux-disease-with-esophagitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection caused by Helicobacter pylori","diseaseId":"infection-caused-by-helicobacter-pylori","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05582174","phase":"PHASE4","title":"PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-18","conditions":"Upper GI Bleeding, Proton Pump Inhibitors","enrollment":594},{"nctId":"NCT03214081","phase":"","title":"Special Drug Use Surveillance of Vonoprazan for \"Maintenance Therapy of Reflux Esophagitis: Long-term Use\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-01","conditions":"Reflux Esophagitis","enrollment":1237},{"nctId":"NCT03214198","phase":"","title":"Special Drug Use Surveillance of Vonoprazan for \"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-09-01","conditions":"A History of Gastric or Duodenal Ulcers","enrollment":1304},{"nctId":"NCT05135793","phase":"PHASE1","title":"Bioequivalence Study of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2021-01-19","conditions":"Healthy","enrollment":29},{"nctId":"NCT04568772","phase":"PHASE1","title":"Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-11-25","conditions":"Gastroesophageal Reflux Disease","enrollment":19},{"nctId":"NCT03214094","phase":"","title":"Special Drug Use Surveillance of Vonoprazan for \"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-09-01","conditions":"Gastric or Duodenal Ulcers","enrollment":1119},{"nctId":"NCT03214952","phase":"","title":"Drug Use Surveillance of Vonoprazan for \"Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-01","conditions":"Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis","enrollment":3183},{"nctId":"NCT02827942","phase":"PHASE3","title":"Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication","status":"COMPLETED","sponsor":"Hamamatsu University","startDate":"2016-07-01","conditions":"Gastritis Associated With Helicobacter Pylori","enrollment":112},{"nctId":"NCT03219723","phase":"","title":"Drug Use Surveillance of Takecab for \"Supplement to Helicobacter Pylori Eradication\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-09-01","conditions":"Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other","enrollment":560},{"nctId":"NCT02037477","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-01","conditions":"Healthy Volunteers","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_1","status":"active","brandName":"Takecab","genericName":"Takecab","companyName":"Genuine Research Center, Egypt","companyId":"genuine-research-center-egypt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vonoprazan, a small molecule, is used to treat various gastrointestinal conditions, including Reflux Esophagitis, Gastroesophageal Reflux Disease, and Gastric/Duodenal Ulcer, among others. It is administered in combination with Amoxicillin 500 mg tid, as seen in clinical trials such as NCT03214081.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Takecab","application_number":"Takecab"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}